A Phase 2 Non-Comparative Randomized Open-Label Study of Multiple Regimens of Single-Agent XL184 in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse.

Trial Profile

A Phase 2 Non-Comparative Randomized Open-Label Study of Multiple Regimens of Single-Agent XL184 in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2014

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Astrocytoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Exelixis
  • Most Recent Events

    • 29 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Aug 2012 Planned End Date changed from 1 Jan 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 01 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top